United Kingdom

People: CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

23 Aug 2019
Change (% chg)

$-2.23 (-4.56%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Behbahani, Ali 

Dr. Ali Behbahani, M.D., has been Independent Director of CRISPR Therapeutics Ltd since April 2015. He joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. He concurrently earned his M.D. degree from the University of Pennsylvania School of Medicine and his MBA degree from the University of Pennsylvania Wharton School, where he graduated with honors and was a Palmer Scholar. He graduated Summa Cum Laude and received his B.S.E., B.M.E. and E.E. degrees with distinction in biomedical engineering, electrical engineering and chemistry from Duke University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --